Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview CMIC's With Moriaki Akasaki (Pt. 2)
This article was originally published in The Pink Sheet Daily
CMIC executive discusses quality control and informed consent, and the meaning of "extravagent" trials under Japanese regulations.
You may also be interested in...
Japan's First CRO On How ICH Affects Clinical Trials in Japan: An Interview With CMIC Exec Moriaki Akasaki
CMIC was established in 1992 and now is Japan's largest contract research organization, with more than 2,500 employees.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.